Quantcast

Latest H5N1 Stories

b08b450dda0171725fc3c0d5739d4c25
2011-07-15 07:45:00

The United Nations' World Health Organization said on Thursday that worldwide production of seasonal flu vaccine is expected to double to 1.7 billion doses by 2015, with eleven new manufacturers ramping up in developing nations, Reuters reports. Furthermore, in the event of a new influenza pandemic, a projected 37 vaccine makers could potentially triple their annual production of trivalent seasonal vaccine to produce some 5.4 billion doses, the U.N. agency said. However, experts say the...

2011-07-14 03:00:00

BLUE BELL, Pa., July 14, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon(TM) DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation. These results were presented at DNA Vaccines 2011,...

2011-06-30 06:00:00

- Phase II part B confirms results obtained in Phase II part A - - Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - QUEBEC CITY, June 30, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with...

27a9e6dab4eb5b5173e479ad14868a9f
2011-06-09 05:05:00

The need to create a new flu vaccine annually could be eliminated with a universal influenza vaccine that targets a protein common to all strains of influenza A, which has been able to safely produce an immune response in humans, according to a study published in the journal Vaccine. If proven effective, it will have major implications for global health. Two studies were conducted, one at the University of Texas Medical Branch at Galveston (UTMB) and one at Johnson County Clin-Trials in...

2011-06-08 06:00:00

- All tested doses were found safe and well-tolerated - - A single dose of 5 µg met the 3 CHMP immunogenicity criteria - QUEBEC CITY, June 8, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive results from a U.S. Phase I human clinical trial with its seasonal influenza vaccine...

2011-06-07 08:10:00

SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has begun dosing volunteers in a Phase I clinical trial. This is the first clinical study evaluating a vaccine that uses the company's novel oral-vaccine platform technology. The trial site is in the United States. "This first trial in humans is important, because if safety is demonstrated with one vaccine, we can expect that later vaccines using the same...

2011-06-07 07:00:00

BEIJING, June 7, 2011 / PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2011 Annual Meeting of Shareholders on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple Street, St. John's, Antigua. All shareholders of record as of May 25, 2011 will be eligible to vote and are invited...

2011-05-27 16:00:00

QUEBEC CITY, QUEBEC, May 27, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced its operational and financial results for the first quarter ended March 31, 2011. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "We recently achieved positive phase II...

2011-05-09 07:00:00

ROCKVILLE, Md., May 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results for the first quarter ended March 31, 2011. The company reported a net loss of $7.5 million, or $0.07 per share, for the first quarter of 2011, compared to a net loss of $10.3 million, or $0.10 per share, for the first quarter of 2010. The primary reason for the decreased loss during the quarter was due to lower research and development spending to support clinical trials of the...

2011-05-09 07:00:00

BEIJING, May 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to present at two upcoming investor conferences in New York City. Piper Jaffray 8th Annual China Growth Conference Sinovac is scheduled to present at 4:00 pm on Tuesday, May 17, 2011 and will be participating in one-on-one meetings...


Latest H5N1 Reference Libraries

0_4ca1489f40c064454e50358dffa2e208
2011-02-17 15:02:05

Influenza A virus causes influenza in birds and some mammals. It is a genus of the Orthomyxoviridae family of viruses. Although the virus is uncommon several strains have been isolated from wild birds. Some can cause severe disease in domestic poultry and sometimes in humans. They are negative sense, single-stranded, segmented RNA viruses. Each subtype has mutated into a variety of strains with different pathogenic profiles. There is a vaccine for humans incase there is an avian influenza, or...

More Articles (1 articles) »
Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related